CanFinis Pipeline
Advanced CAR-T Product
Canfinis Therapeutics stands out with its Advanced CAR-T Product, poised for a potential gastro-intestinal cancer clinical trial soon, demonstrating our ability to rapidly bring cutting-edge therapies to market. In addition, our robust pipeline includes 4 other CAR-T products in various stages of development, showcasing a diverse and expanding portfolio. This unique combination of clinical readiness and pipeline depth represents a significant value addition and solidifies the company’s position as a high-potential player in the CAR-T space. These assets provide us with both near-term and long-term growth opportunities.
Product | Description | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
CF-003 | CAR-Ts for Metastatic Gastric Cancers | Manufacturing & Phase I | Phase II | Approval | Commercial |
CF-005 | CAR-Ts for Primary Gastric Cancers | Preclinical | Manufacturing | Phase I & Phase IIa | |
CF-007 | CAR-Ts for other metastatic cancer in the peritoneal cavity | Early Preclinical | Preclinical | Manufacturing | |
CF-009 | CAR-Ts for Mesothelioma & Lung cancer | Target Selection | Discovery and Lead IDs | Preclinical POC | |
CF-011 | CAR-Ts for Metastatic Prostate cancer | Target Selection | Discovery and Lead IDs | Preclinical POC |